Another study in mice of AD reported similar findings that oral DPP4i administration (Linagliptin) can significantly improve incretin levels and reduce Aβ deposition, tau phosphorylation and neuroinflammation in the brain (Kosaraju et al., 2017). Here, MAPT is linked to Alzheimer disease.